Investors are worried how the company will handle the 2028 expiration of the U.S. patents protecting Keytruda, Merck’s ...

Thomas Edward Fuller III, of the 2000 block of Kriebel Road in Towamencin and also of Dana Avenue in Bensalem, was charged ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or 'the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck (NYSE:MRK) on Tuesday reported second-quarter earnings and revenue that beat and missed analyst expectations, respectively, while narrowing its outlook for the year.

Berkshire Hathaway Selling Part of Verisign Stake; Stock Falling After-Hours The price of the offering hasn't been set yet but it could raise $1.2 billion based on Verisign's stock price in ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

Sales of Keytruda, which accounts for about half of Merck's revenue, grew by 9%, to $7.96 billion. Merck's main U.S. patent for the cancer treatment expires in 2028, opening the door for lower-cost ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.76. Earnings, adjusted for one-time gains and costs, were $2.13 per share. The results topped Wall Street ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...